Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE

Published 2018 View Full Article

Authors

Keywords

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 36, Issue 8, Pages 741-748

Publisher

American Society of Clinical Oncology (ASCO)

Online

2017-12-16

DOI

10.1200/jco.2017.74.7824

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

JOURNAL OF CLINICAL ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Discover Peeref hubs

Ask a Question. Answer a Question.